Dennis Massimo and his sister Lauren Massimo in 2026.
(Image: Courtesy of Penn Medicine News)
Learning I had Lynch syndrome ‘saved my life’
Dennis Massimo was only 42 and symptom-free when he was diagnosed with colorectal cancer, thanks to a research study he signed up for with the Penn Medicine BioBank nearly a decade earlier.
First CRISPR-based platform to pinpoint leukemia drivers
The new toolkit, developed by Penn Medicine and Children’s Hospital of Philadelphia, allows researchers to test potential cancer targets directly in patient leukemia cells.
Penn Medicine clinicians are using a less intense form of radiation therapy typically used for cancer treatment to help bring patients relief from other conditions.
Image: Sebastian Kaulitzk/Science Photo Library via Getty Images
Investigational blood biomarker panel may improve detection of pancreatic cancer
A Penn Medicine study shows that a biomarker blood panel that incorporates four different proteins enhances the detection of pancreatic cancer compared to measuring CA19-9 levels alone.
Kateryna Kon/Science Photo Library via Getty Images
New CAR T strategy targets most common form of heart disease
Preclinical research from investigators at Penn Medicine shows that experimental CAR T cells block inflammation in arteries, preventing more than two-thirds of the plaque buildup seen in untreated controls.
Donita Brady (center), Harrison McCrea Dickson, M.D. and Clifford C. Baker, M.D. Presidential Professor.
(Image: Margo Reed)
Maximizing access to science with Penn Medicine’s Donita Brady
Brady, the 2026 recipient of the American Society for Biochemistry and Molecular Biology Ruth Kirschstein Award for Maximizing Access in Science, shares her approach to creating opportunities for all.
Enhanced CAR T cell therapy offers new strategy for lymphoma
A new study from Penn Medicine marks a significant development in the ongoing evolution of CAR T cell therapy, as a novel cytokine-enhanced CAR T that has been tested in patients with blood cancer shows robust response rates.
Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer
A preclinical study from the Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center that combines RAS inhibition and immunotherapy shows promise for future clinical trials in pancreatic cancer treatment strategies.
